$GERN

GERON CORP

Geron is a commercial-stage biopharmaceutical company that develops and commercializes treatments for blood cancers. Its main product is RYTELO (imetelstat), a telomerase inhibitor approved in the United States and European Union for certain adults with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes. Geron launched RYTELO in the United States in June 2024 and plans to work with third parties on commercialization in select EU markets. It also makes RYTELO available outside the United States through Named Patient Programs with distributor Tanner Pharma. Geron is studying imetelstat in clinical trials for myelofibrosis and other blood cancers, and has a discovery program for potential next-generation oral telomerase inhibitors. The company holds global commercial rights to RYTELO. It is headquartered in Foster City, California.

No enriched coverage for $GERN in the last 7 days.

$62K
—
Semerjian Harout
0%
See all $GERN insider activity →

Geron Targets Germany Launch and Deals as RYTELO Sales Grow

Geron (GERN) plans to launch RYTELO in Germany, aiming to set a price before the country's pricing process. The company expects higher SGA expenses next year but has reduced operating costs by $10M this year. After discontinuing a Phase 3 trial, Geron focuses on growing its business, expanding RYTELO internationally, and pursuing deals. The company reported profitability in the latest quarter and believes it has sufficient cash for future operations.

GERN sentiment & insider activity

Recent GERN coverage spans financial news, insider activity and earnings.

In the last 30 days, GERN insiders filed 2 SEC Form 4 transactions — 2 purchases ($62K) and no sales. The most active reporter was Semerjian Harout, President & CEO, with 1 filing.

What's driving GERN

AlphAI scores every news story that mentions GERN with an AI model for sentiment and relevance, and aggregates insider trades from GERON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GERN

Score

Geron Targets Germany Launch and Deals as RYTELO Sales Grow

Geron (GERN) plans to launch RYTELO in Germany, aiming to set a price before the country's pricing process. The company expects higher SGA expenses next year but has reduced operating costs by $10M this year. After discontinuing a Phase 3 trial, Geron focuses on growing its business, expanding RYTELO internationally, and pursuing deals. The company reported profitability in the latest quarter and believes it has sufficient cash for future operations.

$GERNMedAI 8/10Clinical / regulatory· discontinuation

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

GERON CORP (GERN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis FOSTER CITY, Calif., – October 28, 2026 – Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announce

Wedbush cuts Geron stock price target to $5 on study halt

Wedbush reduced its price target for Geron (GERN) to $5 from $6, citing the discontinuation of the IMpactMF study, but maintained an Outperform rating. The firm noted no new safety signals and expects Rytelo's commercial trajectory to remain intact. Geron reported $57.5M in Q2 2026 revenue, up 11% sequentially, and 24% year-over-year growth over the last twelve months. The stock trades near its 52-week low of $1.04.

$GERNMedAI 8/10

A blood cancer trial is set to stop after monitors say it is unlikely to meet its survival goal.

Geron Corporation (GERN) will discontinue its Phase 3 IMpactMF trial for imetelstat in myelofibrosis after the Data Monitoring Committee advised it was unlikely to meet the primary survival endpoint. The company will analyze the data and share findings later. Geron remains focused on its commercial business and growing demand for RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS).

$GERNMedAI 8/10

In a 58-patient U.S. study, about 67% remained on Geron's treatment at six months.

Geron Corporation (GERN) presented data on imetelstat, its treatment for lower-risk myelodysplastic syndromes (LR-MDS), at two hematology conferences. A U.S. study showed 67% of 58 patients remained on treatment at six months. The company highlighted real-world evidence and clinical trial results, emphasizing global interest in imetelstat. Geron aims to expand its use in LR-MDS and other hematologic malignancies.

Related tickers